Compare JPMorgan Equity Premium Income ETF (JEPI) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Equity Premium Income ETF vs Organon & Co. Common Stock — how do they compare? JPMorgan Equity Premium Income ETF trades at $56.96 (market cap $45.69B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: JPMorgan Equity Premium Income ETF is far larger — about 12.6× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while JPMorgan Equity Premium Income ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Equity Premium Income ETF for 58 Days and Organon & Co. Common Stock for 0 Days on average.
| JEPI | OGN | |
|---|---|---|
Market Cap | $45.69B | $3.62B |
Volume | 3,633,306 | 2,892,999 |
Sector | Income / Options Overlay | Health |
52-Week High | $59.88 | $13.81 |
52-Week Low | $55.29 | $5.70 |
Typical Hold Time | 58 Days | 0 Days |
Enterprise Value | — | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JEPI trades at $56.93 with minimal daily movement (-0.05%) and maintains a bullish technical outlook based on moving averages. The ETF continues its consistent dividend distribution strategy with recent payments of $0.37 per share. Technical indicators show mixed signals with RSI levels ranging from neutral to overbought, while the overall trend remains positive.
The covered-call strategy provides income stability but may limit upside during strong market rallies. Recent media coverage highlights JEPI's role in retirement income strategies, though investors should consider tax implications and income limitations compared to pure equity exposure.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About JPMorgan Equity Premium Income ETF
JEPI is an actively managed ETF that seeks to deliver monthly income and stock market exposure with lower volatility. It combines an equity portfolio with an options strategy to generate steady premiums.
Read more on JEPI →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
